TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.